Denecke T, Rau B, Hoffmann K-T, Hildebrandt B, Ruf J, Gutberlet M, Hünerbein M, Felix R, Wust P, Amthauer H
Klinik für Strahlenheilkunde und PET-Zentrum Berlin Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
Eur Radiol. 2005 Aug;15(8):1658-66. doi: 10.1007/s00330-005-2658-4. Epub 2005 Apr 2.
The aim of this study was to compare CT, MRI and FDG-PET in the prediction of outcome of neoadjuvant radiochemotherapy in patients with locally advanced primary rectal cancer. A total of 23 patients with T3/4 rectal cancer underwent a preoperative radiochemotherapy combined with regional hyperthermia. Staging was performed using four-slice CT (n=23), 1.5-T MRI (n=10), and (18)F-FDG-PET (n=23) before and 2-4 weeks after completion of neoadjuvant treatment. Response criteria were a change in T category and tumour volume for CT and MRI and a change in glucose uptake (standard uptake value) within the tumour for FDG-PET. Imaging results were compared with those of pretherapy endorectal ultrasound and histopathological findings. Histopathology showed a response to neoadjuvant therapy in 13 patients whereas 10 patients were classified as nonresponders. The mean SUV reduction in responders (60+/-14%) was significantly higher than in nonresponders (37+/-31%; P=0.030). The sensitivity and specificity of FDG-PET in identifying response was 100% (CT 54%, MRI 71%) and 60% (CT 80%, MRT 67%). Positive and negative predictive values were 77% (CT 78%, MRI 83%) and 100% (CT 57%, MRI 50%) (PET P=0.002, CT P=0.197, MRI P=0.500). These results suggest that FDG-PET is superior to CT and MRI in predicting response to preoperative multimodal treatment of locally advanced primary rectal cancer.
本研究旨在比较CT、MRI和FDG-PET在预测局部晚期原发性直肠癌患者新辅助放化疗疗效方面的作用。共有23例T3/4期直肠癌患者接受了术前放化疗联合区域热疗。在新辅助治疗开始前及结束后2 - 4周,分别采用四排CT(n = 23)、1.5-T MRI(n = 10)和(18)F-FDG-PET(n = 23)进行分期。CT和MRI的反应标准为T分期和肿瘤体积的变化,FDG-PET的反应标准为肿瘤内葡萄糖摄取(标准摄取值)的变化。将影像学结果与治疗前直肠内超声及组织病理学结果进行比较。组织病理学显示,13例患者对新辅助治疗有反应,10例患者被归类为无反应者。有反应者的平均SUV降低率(60±14%)显著高于无反应者(37±31%;P = 0.030)。FDG-PET识别反应的敏感性和特异性分别为100%(CT为54%,MRI为71%)和60%(CT为80%,MRT为67%)。阳性和阴性预测值分别为77%(CT为78%,MRI为83%)和100%(CT为57%,MRI为50%)(PET P = 0.002,CT P = 0.197,MRI P = 0.500)。这些结果表明,在预测局部晚期原发性直肠癌术前多模式治疗的反应方面,FDG-PET优于CT和MRI。